Collegium Pharmaceutical announced the publication of results from the Phase III clinical trial of Xtampza ER (oxycodone extended-release capsules). The...
Collegium Pharmaceutical announced that the FDA has granted tentative approval to the company's New Drug Application (NDA) for Xtampza ER...
Collegium Pharmaceutical has announced the publication of an analysis of the duration of effect of Xtampza ER (oxycodone extended-release capsules)...
The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted...
Pain Therapeutics announced two new publications for its drug candidate, Remoxy ER (extended-release oxycodone). The studies are published in Journal...
Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
The FDA has approved a new, harder-to-abuse formulation of Opana ER, the extended-release oxymorphone drug that is crush resistant from...
Osmotica Pharmaceutical announced that the FDA has approved Osmolex ER (amantadine HCl extended release), for the treatment of Parkinson's disease...